2. Signaling Pathways
  3. Protein Tyrosine Kinase/RTK
  4. Src

Src

Src

Related Products

PDF 1.28 MB

Src family kinase (SFK) is a family of non-receptor tyrosine kinases including nine members: Src, Yes, Fyn, and Fgr, forming the SrcA subfamily, Lck, Hck, Blk, and Lyn in the SrcB subfamily, and Frk in its own subfamily. In immune cells, Src-family kinases (SFKs) have been implicated as critical regulators of a large number of intracellular signaling pathways. Src-family kinases (SFKs) occupy a proximal position in numerous signaling transduction cascades including those emanating from the T and B cell antigen receptors, Fc receptors, growth factor receptors, cytokine receptors, and integrins. In addition to these positive regulatory roles, Src-family kinases (SFKs) can also function as negative regulators of cellular signaling by phosphorylating immunoreceptor tyrosine-based inhibitory motifs (ITIMs) on inhibitory receptors, resulting in recruitment and activation of inhibitory molecules such as the phosphatases SHP-1 and SH2 containing 5′ inositol phosphatase (SHIP-1).

Src Isoform Specific Products:

Src Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-175809
    SRT6
    		Inhibitor
    SRT6, an anticancer agent is a CD44 inhibitor. SRT6 inhibits key CD44-associated kinases, including SRC, ERBB2 and MAPKAPK2. SRT6 has strong tumor selectivity over non-tumoral lung cells and significant antiproliferative activity against cancer cells (EC50of 1.37  μM for NCI-H23 cells).
    SRT6
  • HY-N0202R
    Atractylenolide II (Standard)
    		Inhibitor
    Atractylenolide II (Standard) is the analytical standard of Atractylenolide II. This product is intended for research and analytical applications. Atractylenolide II (Asterolide) is a sesquiterpenoid compound. Atractylenolide II can induce G1 phase cell cycle arrest and apoptosis in B16 melanoma cells. Atractylenolide II is an orally effective anticancer agent that can exert anti-melanoma effects by inhibiting the STAT3 signaling pathway. In addition, Atractylenolide II has been shown to ameliorate myocardial fibrosis, oxidative stress, and neuroprotective activity.
    Atractylenolide II (Standard)
  • HY-168893
    K882
    		Inhibitor
    K882 (Compound 4e) is a Src inhibitor, with KD of 0.315 μM. K882 induces Apoptosis. K882 inhibits XIAP and Survivin. K882 inhibits the activation of PI3K/Akt/mTOR, Jak1/Stat3, Ras/MAPK signaling pathways. K882 shows anti-tumor activity against non-small cell lung cancer.
    K882
  • HY-W844558
    Protein kinase inhibitor 11
    		Inhibitor 98.28%
    Protein kinase inhibitor 11 (Compound I-96) is a protein kinase inhibitor that can inhibit the activity of PIM-1, CDK-2, GSK-3, and SRC. Protein kinase inhibitor 11 holds promise for research in cancer, immune disorders, and neurodegenerative diseases.
    Protein kinase inhibitor 11
  • HY-128397
    CpCDPK1/TgCDPK1-IN-1
    		Inhibitor
    CpCDPK1/TgCDPK1-IN-1 (compound 7p) is a potent CpCDPK1/TgCDPK1 dual inhibitor (IC50: 10 nM and 5.0 nM respectively). CpCDPK1/TgCDPK1-IN-1 also inhibits Abl and Src (IC50: 75 nM and 65 nM respectively). CpCDPK1/TgCDPK1-IN-1 can be used for research of toxoplasmosis.
    CpCDPK1/TgCDPK1-IN-1
  • HY-175437
    MRT-7612
    		Degrader
    MRT-7612 (Compound 4) is a cereblon-based tyrosine kinases molecular glue degrader. MRT-7612 significantly induces HCK and LYN degradation, with week efficacy on LCK. MRT-7612 can be used for cancers like chronic myeloid leukemia, autoimmune and chronic inflammatory diseases research.
    MRT-7612
  • HY-E70725
    FRK Recombinant Human Active Protein Kinase
    FRK Recombinant Human Active Protein Kinase, a non-receptor tyrosine kinase Fyn-related kinase, is a member of the BRK family kinases (BFKs). FRK may be involved in tumor progression.
    FRK Recombinant Human Active Protein Kinase
  • HY-P10527
    CSK substrate
    CSK substrate is a specific substrate for C-terminal Src kinase (CSK), which binds CSK and downregulates the Src family members. CSK substrate preferentially phosphorylates certain amino acid residues that are distinct from the conserved Src C-terminal sequence.
    CSK substrate
  • HY-131931
    Lysoganglioside-GM1 potassium
    		Inhibitor
    Lysoganglioside-GM1 (LysoGM1) potassium is a derivative of Monosialoganglioside GM1, which lacks a fatty acid. Lysoganglioside-GM1 potassium is also an inhibitor of GM1 aggregation. Lysoganglioside-GM1 potassium can inhibit the activation of Lyn and laminin-1-mediated neurite outgrowth. Lysoganglioside-GM1 potassium can be used in the research of nervous system diseases.
    Lysoganglioside-GM1 potassium
  • HY-10158AR
    Bosutinib hydrate (Standard)
    		Inhibitor
    Bosutinib (Standard) (SKI-606 (Standard)) hydrate is the analytical standard of Bosutinib hydrate (HY-10158A). This product is intended for research and analytical applications. Bosutinib hydrate is an oraly activel Src/Abl tyrosine kinase inhibito with IC50s of 1.2 nM and 1 nM, respectively.
    Bosutinib hydrate (Standard)
  • HY-P10372
    pFYN peptide
    pFYN peptide is a biotin-labled phosphorylated peptide substrate derived from FYN (a Src family kinase).
    pFYN peptide
  • HY-139890
    DC-Srci-6649
    		Inhibitor
    DC-Srci-6649 is a c-Src kinase inhibitor that inhibits the phosphorylation and locks c-Src in the inactive state.
    DC-Srci-6649
  • HY-150026
    Multi-kinase-IN-2
    		Inhibitor
    Multi-kinase-IN-2 (compound 7h) is an orally active and potent angiokinase inhibitor. Multi-kinase-IN-2 exhibits excellent inhibitory activity against angiokinases including VEGFR-1/2/3, PDGFRα/β, and FGFR-1, as well as LYN and c-KIT kinases. Multi-kinase-IN-2 significantly attenuates phosphorylation of AKT and ERK proteins. Multi-kinase-IN-2 induces cell apoptosis. Multi-kinase-IN-2 shows anticancer activity.
    Multi-kinase-IN-2
  • HY-175281
    SJ11646
    		Degrader
    SJ11646 is a Dasatinib (HY-10181)-based LCK PROTAC degrader with a DC50 of 0.00838 pM. SJ11646 has potent cytotoxicity against LCK-activated T-cell acute lymphoblastic leukemia (T-ALL) cells and primary leukemia samples with drastically prolonged suppression of LCK signaling, and induces T-ALL apoptosis. SJ11646 binds to 51 human kinases with a high affinity (particularly ABL1, KIT, and DDR1). SJ11646 has superior antileukemic efficacy in T-ALL mice model. . Pink: LCK ligand (HY-107447); Blue: CRBN ligase ligand (HY-163169); Black: linker (HY-76667)
    SJ11646
  • HY-163468
    SRC-3-IN-1
    		Inhibitor
    SRC-3-IN-1 (compound SI-10) is a steroid receptor coactivator 3 (SRC-3) inhibitor (IC50=3.3 μM). SRC-3-IN-1 has good water solubility, oral bioavailability, and improved selectivity profile. SRC-3-IN-1 can be used in prostate cancer research.
    SRC-3-IN-1
  • HY-110367
    LCB 03-0110 dihydrochloride
    		Inhibitor
    LCB 03-0110 dihydrochloride is a dihydrochloride of LCB 03-0110. LCB 03-0110 is a potent inhibitor of Src family tyrosine kinase.
    LCB 03-0110 dihydrochloride
  • HY-163278
    Lck-IN-2
    		Inhibitor
    Lck-IN-2 (compound 12a) is an inhibitor of Lymphocyte-specific protein tyrosine kinase (Lck) with IC50 of 10.6 nM. Lck-IN-2 reveals efficacy in colon cancer cells with GI50s of 0.24-1.26 μM. Lck-IN-2 exhibits an apoptotic effect in Colo201 cells.
    Lck-IN-2
  • HY-P1200
    Ac-Tyr(PO3H2)-Glu-Glu-Ile-Glu-OH
    		Inhibitor
    Ac-Tyr(PO3H2)-Glu-Glu-Ile-Glu-OH (compound 1) is a high-affinity pentapeptide to bind to the src SH2 domain (IC50≈1 µM). Ac-Tyr(PO3H2)-Glu-Glu-Ile-Glu-OH is an inhibitor for src SH3-SH2:phosphoprotein interactions.
    Ac-Tyr(PO3H2)-Glu-Glu-Ile-Glu-OH
  • HY-178120
    Lck-IN-4
    		Inhibitor
    Lck-IN-4 (Compound A-1) is a protein tyrosine kinase Lck inhibitor with an IC50 of 2  nM. Lck-IN-4 significantly inhibits YAP tyrosine phosphorylation and activity and induces apoptosis in cholangiocarcinoma CCA cells. Lck-IN-4 is cytotoxic in CCA tumor-derived organoids with elevated YAP activity Lck-IN-4 can be used for cancers like cholangiocarcinoma (CCA) research.
    Lck-IN-4
  • HY-18507A
    AD57 hydrochloride
    		Inhibitor
    AD57 hydrochloride is an orally active multikinase inhibitor, inhibits RET, BRAF, S6K and Src.
    AD57 hydrochloride
Cat. No. Product Name / Synonyms Application Reactivity
Src Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.